Tofisopam

Tofisopam (marketed under brand names Emandaxin and Grandaxin) is a drug which is a benzodiazepine derivative. Like other benzodiazepines, it possesses anxiolytic properties but unlike other benzodiazepines it does not have anticonvulsant, sedative,^[1] skeletal muscle relaxant, motor skill-impairing or amnestic^[2] properties. While it may not be an anticonvulsant in and of itself, it has been shown to enhance the anticonvulsant action of classical 1,4-benzodiazepines such as diazepam (but not sodium valproate, carbamazepine, phenobarbital, or phenytoin).^[3] Tofisopam is indicated for the treatment of anxiety and alcohol withdrawal, and is prescribed in a dosage of 50 - 300mg per day divided into three doses. Peak plasma levels are attained two hours after an oral dose. Tofisopam is not reported as causing dependance to the same extent as other benzodiazepines, but is still recommended to be prescribed for a maximum of 12 weeks. ^[4]

Additional recommended knowledge

How to quickly check pipettes?

Safe Weighing Range Ensures Accurate Results

Correct Test Weight Handling Guide: 12 Practical Tips

Tofisopam is not approved for sale in the United States or Canada. However, Vela Pharmaceuticals of New Jersey is developing the D- enantiomer (dextofisopam) as a treatment for irritable bowel syndrome.^[5]

References